GlassScriptPhysician profile
James F Gallagher
NPI 1447239504
$2,261.03
in general payments reported to CMS, 2019-2025
20 companies · $726 in 2025
The $726 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $53.92 · 2021: $93.85 · 2022: $187 · 2023: $216 · 2024: $538 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $344.40 | 2022-2025 | |
| Alcon Vision LLC | $308.20 | 2019-2024 | Clareon |
| Tarsus Pharmaceuticals, INC. | $300.28 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $288.78 | 2024-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Mallinckrodt Hospital Products INC. | $184.04 | 2021-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $139.73 | 2022-2025 | Cequa |
| Regeneron Healthcare Solutions, INC. | $120.11 | 2019 | |
| Aerie Pharmaceuticals, INC. | $112.18 | 2019 | |
| Rayner Intraocular Lenses Limited | $96.65 | 2022-2025 | Omidria, Rayone Emv, Rayone Aspheric |
| Oyster Point Pharma, INC. | $95.20 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $61.35 | 2024-2025 | Oxervate |
| Allergan, INC. | $58.74 | 2019-2020 | |
| Biotissue Holdings INC. | $26.56 | 2024 | |
| Kala Pharmaceuticals, INC. | $20.50 | 2019 | |
| Bausch & Lomb Americas INC. | $20.02 | 2024 | Xiidra, Miebo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $19.93 | 2021 | |
| Sight Sciences, INC. | $17.92 | 2022 | |
| Ivantis, INC | $16.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.56 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.